6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03568968 (ClinicalTrials.gov) | May 15, 2020 | 14/6/2018 | A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease | A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study | Parkinson Disease | Dietary Supplement: Nicotinamide Riboside;Drug: Placebo | Haukeland University Hospital | NULL | Recruiting | 18 Years | N/A | All | 400 | N/A | Norway |
| 2 | NCT03816020 (ClinicalTrials.gov) | March 9, 2019 | 7/12/2018 | NAD-supplementation in Drug naïve Parkinson's Disease | NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease | Parkinson Disease;Neurodegenerative Diseases | Dietary Supplement: Nicotinamide Riboside;Other: Placebo | Haukeland University Hospital | NULL | Completed | 18 Years | N/A | All | 30 | N/A | Norway |
| 3 | NCT03865121 (ClinicalTrials.gov) | March 4, 2019 | 26/2/2019 | Pilot Trial of Transnasal Nicotine in Parkinson Disease | Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease | Parkinson Disease | Drug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | Howard University | Completed | 60 Years | N/A | All | 6 | Phase 2 | Mexico |
| 4 | NCT02452125 (ClinicalTrials.gov) | May 2015 | 20/5/2015 | The Effects of Nicotine Chewing Gum in Parkinson's Disease | The Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's Disease | Low Blood Pressure;Parkinsons Disease | Dietary Supplement: Nicotine gum | New York Institute of Technology | NULL | Completed | N/A | N/A | All | 10 | N/A | United States |
| 5 | JPRN-UMIN000016664 | 2015/03/01 | 01/03/2015 | Effect of nicotine patch in Cognitive function improvement in Parkinson's disease | Parkinson's disease | nicotine patch | Department of Clinical Pharmacology and Neurology Ehime University graduated School of Medicine | NULL | Recruiting | Not applicable | Not applicable | Male and Female | 20 | Not selected | Japan | |
| 6 | NCT01560754 (ClinicalTrials.gov) | October 2012 | 9/3/2012 | Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease | A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USA | Parkinson's Disease | Drug: nicotine transdermal patch | James BOYD MD | Michael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkinson Fonds (IPF);German Parkinson Study Group (GPS);German Parkinson Society (DPG);Philipps-University Marburg, Germany | Active, not recruiting | 30 Years | N/A | Both | 160 | Phase 2 | United States;Germany |
| 7 | EUCTR2010-020299-42-DE (EUCTR) | 30/08/2011 | 26/04/2011 | A study in U.S. and Germany to show if patients with an early stage of Parkinson's disease could be treated with a nicotine patch. In this study the nicotine patch is being compared to a placebo patch. The placebo patch is identical in appearance to the nicotine patch but does not contain any active ingredients. | A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD) - NIC-PD | Early PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levodopa therapy for 1 year, with Hoehn and Yahr stage <2, with stable (>2 months) MAO-B inhibitor therapy allowed MedDRA version: 16.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Nicotinell 17,5 mg/24-Stunden-Pflaster Product Name: Nicotinell Other descriptive name: NICOTINE Trade Name: Nicotinell 35 mg/24-Stunden-Pflaster Product Name: Nicotinell Other descriptive name: NICOTINE | Philipps-University Marburg | NULL | Not Recruiting | Female: yes Male: yes | 160 | Phase 2 | United States;Germany | ||
| 8 | NCT01216904 (ClinicalTrials.gov) | October 2010 | 6/10/2010 | Nicotine Treatment of Impulsivity in Parkinson's Disease | Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study | Parkinson's Disease | Drug: nicotine patch;Drug: placebo | University of Vermont | Parkinson's Disease Foundation;The Parkinson Study Group | Recruiting | 18 Years | N/A | Both | 20 | Phase 4 | United States |
| 9 | NCT00957918 (ClinicalTrials.gov) | October 2009 | 11/8/2009 | Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy | Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy | Parkinson's Disease | Drug: nicotine;Other: placebo comparator | Neuraltus Pharmaceuticals, Inc. | NULL | Completed | 30 Years | 83 Years | Both | 65 | Phase 1/Phase 2 | United States |
| 10 | NCT00873392 (ClinicalTrials.gov) | February 2009 | 31/3/2009 | Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease | Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease(One Daily Administration).A Controlled Randomised Study, in Two Parallel Groups and Single Blind in 40 Patients. | Idiopathic Parkinson's Disease | Drug: Transdermal nicotine;Other: Usual drug treatment of Parkinson's disease | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 35 Years | 70 Years | Both | 40 | Phase 2 | France |
| 11 | EUCTR2008-001336-13-FR (EUCTR) | 16/07/2008 | 09/06/2008 | Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2 | Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2 | Maladie Parkinson MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease | Trade Name: Nicorette 5 mg/ 16 h Product Name: Nicorette 5 mg/ 16 h INN or Proposed INN: Nicotine Product Name: Nicorette 10mg/ 16 h INN or Proposed INN: Nicotine Product Name: Nicorette 15 mg/ 16 h INN or Proposed INN: Nicotine | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| 12 | EUCTR2004-005034-39-GB (EUCTR) | 17/05/2005 | 20/04/2005 | Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease | Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease | Idiopathic Parkinson's disease | Trade Name: Nicotinamide Product Name: NICOTINAMIDE INN or Proposed INN: Nicotinamide | Queen Elizabeth Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | United Kingdom |